Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020—Report from World Marrow Donor Association

Jöris, Monique; Schmidt, Alexander H.; Bernas, Stefanie N.; Feinberg, Jay; Sacchi, Nicoletta; Elmoazzen, Heidi; Fournier, Diane; Oğuz, Fatma; Oliveira, Danielli C. M.; Yang, K. L.; Mousavi, Seied Asadullah; Moomivand, Soraya; Abecasis, Manuel; Villa, Juliana; Fechter, Mirjam; Seval, Güldane Cengiz; Jeyarajah, Thaneya; Devine, Steven M.; Shaw, Bronwen E.; Galarza, Pablo; Malan, Richard; Harvey, Christopher; Forman, Stephen J.; Foeken, Lydia

doi:10.1038/s41409-022-01667-w

Cited by 11 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, centers reported a decrease in HSCT volume, both for non-malignant and malignant disorders, along with a shift in stem cell source distribution and in patient-level protocols [ 5 , 6 ]. A study from the World Marrow Donor Association examining global trends during the COVID-19 pandemic found that donations from unrelated donors decreased by 3.5% from 2019 to 2020, compared to an average annual growth rate of 3.9% from 2015 to 2019 [ 7 ]. The reasons for this decline are likely multifactorial in nature, including disruption in courier and other services as a consequence of travel restrictions or strained health care systems, and prioritization of patients with acute disease, among other potential factors.…”

Section: Impact Of Covid-19 On Transplant Centers and Clinical Practicesmentioning

confidence: 99%

“…ǂ variable definition of severe disease, *variable follow-up time. Author, site(s) Diagnosis period # HSCT recipients: auto/allo/CAR-T Age, years – median (range) Time since HSCT or CAR-T – median (range) % asymptomatic % hospitalized % required supplemental O2 % required ICU care % require mechanical ventilation % severe COVID ǂ % COVID-specific mortality* % overall mortality* % mortality (by time from diagnosis) Altuntas, Republic of Turkey (Ministry of Health database) 3/11/20–5/29/20 32: 20/12/0 56.5 [ [17] , [18] , [19] ] 100 22 16 22 16 Coll, Spain (national)*not all lab confirmed on or before 7/13/20 113: 42/71/0 Auto:60 [ [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] ] 18 months [ [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] ...…”

Section: Morbidity and Mortality In Hsct Recipientsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and HSCT (Hematopoietic stem cell transplant)

Strasfeld¹

2022

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

Section: Impact Of Covid-19 On Transplant Centers and Clinical Practicesmentioning

confidence: 99%

Section: Morbidity and Mortality In Hsct Recipientsmentioning

confidence: 99%

COVID-19 and HSCT (Hematopoietic stem cell transplant)

Strasfeld¹

2022

Best Practice & Research Clinical Haematology

View full text Add to dashboard Cite

“…As a reflection, volumes for preliminary searches, numbers of infused grafts, and types of grafts requested did not substantially differ between later times in the pandemic and pre-pandemic. Lastly, although some TCs have been hesitant to infuse products from SARS-CoV-2 + donors, our limited data suggest that recipients receiving products from these donors does not adversely affect engraftment or survival ( 4 ).…”

Section: Discussionmentioning

confidence: 93%

Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program

Farhadfar

Newman²,

Novakovich³

et al. 2022

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

BackgroundThe Coronavirus Disease 2019 (COVID-19) pandemic in early 2020 has resulted in an unprecedented level of uncertainty and challenge for the stem cell donor registries. To address these challenges, rapid strategies were implemented by the National Marrow Donor Registry (NMDP) and its network partners. Herein, we aim to report the impact of the COVID-19 pandemic on the collection, utilization of grafts, and short-term outcomes of patients who received stem cell products from COVID-19-positive donors.MethodsNMDP data during the early phase (1 March 2020 through 1 May 2020) of the pandemic were compared to the later phase (1 March 2021 through 1 May 2021). Odds ratios were calculated to determine the impact of the pandemic on graft sources requested by transplant centers (TCs). The Kruskal–Wallis test was used to test the effect of the pandemic on the disease indication, volume of searches, and number of products not infused.ResultsAlthough there was an initial decline in overall donor searches during the early phase of the pandemic, these numbers increased reaching pre-pandemic levels during the later phase. Urgent malignant diseases remained the most common indication for transplant in 2021. The pandemic necessitated cryopreservation of stem cell products due to transportation restrictions as well as clinical uncertainties in managing the virus. Cryopreserved grafts remained the most common requested grafts throughout the pandemic. In the later phase of the pandemic, the total numbers of requests for fresh grafts increased, mostly due to the increase in requests for fresh bone marrow (BM) grafts. As the pandemic continued, TCs became more accepting of cryopreservation, resulting in a reduction in the number of products not infused. Lastly, no short-term deleterious outcomes were noted among the patients who had stem cell products infused from a SARS-CoV-2-positive donor.ConclusionThroughout the pandemic, the NMDP and TCs worked tirelessly to ensure that patients would receive lifesaving grafts when needed. The data reported here, although limited by small numbers, illustrate that transplantation from donors with COVID-19 is feasible and safe.

show abstract

“…While the overall inventory size and usage of the bank is modest on a global scale, continued steady usage diverges from global patterns reported recently [ 6 , 7 ], although usage during the COVID-19 pandemic has been variable, with increased usage in 2020 reported by the EBMT [ 9 ], and modest decrease in usage reported by the WMDA [ 10 ]. Banking of units with high cell counts and enriching the inventory to >60% non-Caucasian units in the CBS’ CBB may have charted a course to greater interest and steady usage at the CBS’ CBB in comparison to some other banks around the world.…”

Section: Discussionmentioning

confidence: 99%

A Portrait of Cord Blood Units Distributed for Transplantation from Canadian Blood Services’ Cord Blood Bank: First Analysis

et al. 2022

View full text Add to dashboard Cite

Background: The Canadian Blood Services Cord Blood Bank (CBS CBB) was created to improve access to stem cell products for transplantation for patients across ethnic groups. An analysis of distributed units is needed to assess the effectiveness of the bank to meet the needs of patients from different ethnic groups. Methods: A descriptive analysis was performed on all cord blood units distributed from the CBS’ CBB as of 30 June 2022. Results: Distribution of the first 60 units based on CBS’ CBB inventory has been linear over time. A similar proportion of cord blood unit (CBU) recipients were pediatric or adult. More than half of the cord blood units (56.7%) were distributed to recipients outside of Canada, and CBUs were used to treat a broad range of hematologic and immune disorders. 43.3% of distributed CBUs were of non-Caucasian ethnicity and 18% were from donors self-reporting as multi-ethnic. The mean total nucleated cell counts and total CD34+ cell counts were 1.9 ± 0.1 × 109 cells and 5.3 ± 0.5 × 106 CD34+ cells, respectively. CD34+ cells per kg (recipient weight) varied significantly between pediatric (age 0–4), adolescent (age 5–17) and adult recipients (age 18 and older) (3.1 ± 0.5, 1.4 ± 0.5 and 0.9 ± 0.07 × 105 CD34+ cells/kg, respectively). HLA matching was 6/6 (15%), 5/6 (47%) or 4/6 (38%). Conclusions: The CBS’ CBB has facilitated the utilization of banked units for patients across a broad range of ages, geographic distribution, ethnicity, and diseases. Distributed units were well matched for HLA alleles and contained robust cell counts, reflecting a high-quality inventory with significant utility.

show abstract

Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020—Report from World Marrow Donor Association

Cited by 11 publications

References 6 publications

COVID-19 and HSCT (Hematopoietic stem cell transplant)

COVID-19 and HSCT (Hematopoietic stem cell transplant)

Neither COVID-19, nor cryopreservation, prevented allogeneic product infusion: A report from the National Marrow Donor Program

A Portrait of Cord Blood Units Distributed for Transplantation from Canadian Blood Services’ Cord Blood Bank: First Analysis

Contact Info

Product

Resources

About